UY27500A1 - Formulación sólida para utilizar como medicamento a base de un derivado de piperazinurea - Google Patents

Formulación sólida para utilizar como medicamento a base de un derivado de piperazinurea

Info

Publication number
UY27500A1
UY27500A1 UY27500A UY27500A UY27500A1 UY 27500 A1 UY27500 A1 UY 27500A1 UY 27500 A UY27500 A UY 27500A UY 27500 A UY27500 A UY 27500A UY 27500 A1 UY27500 A1 UY 27500A1
Authority
UY
Uruguay
Prior art keywords
piperazinurea
derivative
solid formulation
medicinal
medicinal based
Prior art date
Application number
UY27500A
Other languages
English (en)
Spanish (es)
Inventor
Ralph Lipp
Heiko Kranz
Christoph Volkel
Johannes Tack
Herbert Wiesinger
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of UY27500A1 publication Critical patent/UY27500A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
UY27500A 2001-10-18 2002-10-17 Formulación sólida para utilizar como medicamento a base de un derivado de piperazinurea UY27500A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10152351A DE10152351B4 (de) 2001-10-18 2001-10-18 Feste Arzneimittelformulierung für ein Piperazinharnstoffderivat

Publications (1)

Publication Number Publication Date
UY27500A1 true UY27500A1 (es) 2003-06-30

Family

ID=7703496

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27500A UY27500A1 (es) 2001-10-18 2002-10-17 Formulación sólida para utilizar como medicamento a base de un derivado de piperazinurea

Country Status (23)

Country Link
EP (1) EP1435917A1 (fr)
JP (1) JP2005506365A (fr)
KR (1) KR20040047920A (fr)
CN (1) CN1571660A (fr)
AR (1) AR037111A1 (fr)
AU (1) AU2002333896B2 (fr)
BR (1) BR0213340A (fr)
CA (1) CA2463951A1 (fr)
CO (1) CO5580740A2 (fr)
DE (1) DE10152351B4 (fr)
EC (1) ECSP045108A (fr)
HR (1) HRP20040435A2 (fr)
IL (1) IL161166A0 (fr)
MX (1) MXPA04003522A (fr)
NO (1) NO20042022L (fr)
NZ (1) NZ532287A (fr)
PE (1) PE20030472A1 (fr)
PL (1) PL367987A1 (fr)
RS (1) RS32204A (fr)
RU (1) RU2311172C2 (fr)
UY (1) UY27500A1 (fr)
WO (1) WO2003035037A1 (fr)
ZA (1) ZA200403781B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040015298A (ko) 2001-06-27 2004-02-18 스미스클라인 비참 코포레이션 디펩티딜 펩티다제 억제제로서의 플루오로피롤리딘
EP1749519A1 (fr) * 2005-08-05 2007-02-07 Schering Aktiengesellschaft Forme galénique à libération prolongée pH-indépendant pour les substances actives avec une solubilité pH-dépendante
US20090169617A1 (en) * 2006-04-26 2009-07-02 Panagiotis Keramidas Controlled Release Formulations Comprising Uncoated Discrete Unit(s) and an Extended Release Matrix
DE102008047910A1 (de) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis
KR101654582B1 (ko) 2016-05-12 2016-09-06 그린로드(주) 원뿔형 부유 고분자 필터, 및 그의 제조장치 및 제조방법, 및 그를 포함하는 수처리 필터
RU2729223C1 (ru) * 2020-05-13 2020-08-05 Мераб Георгиевич Чикобава Дозированная форма для амплификации нуклеиновых кислот

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207665B1 (en) * 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
TR200002248T2 (tr) * 1998-02-05 2000-12-21 Pfizer Products Inc. Yeni dihidroksiheksanoik asit türevleri
EP1027885B1 (fr) * 1999-02-09 2008-07-09 Pfizer Products Inc. Compositions de médicaments basiques avec une meilleure biodisponibilité

Also Published As

Publication number Publication date
AU2002333896B2 (en) 2007-07-26
RU2004115328A (ru) 2005-06-10
AR037111A1 (es) 2004-10-20
NZ532287A (en) 2007-04-27
DE10152351A1 (de) 2003-05-08
RS32204A (en) 2006-10-27
MXPA04003522A (es) 2004-07-23
IL161166A0 (en) 2004-08-31
BR0213340A (pt) 2004-10-05
ECSP045108A (es) 2004-06-28
CN1571660A (zh) 2005-01-26
CA2463951A1 (fr) 2003-05-01
JP2005506365A (ja) 2005-03-03
WO2003035037A1 (fr) 2003-05-01
ZA200403781B (en) 2004-11-29
KR20040047920A (ko) 2004-06-05
RU2311172C2 (ru) 2007-11-27
PL367987A1 (en) 2005-03-21
CO5580740A2 (es) 2005-11-30
EP1435917A1 (fr) 2004-07-14
AU2002333896A2 (en) 2003-05-06
HRP20040435A2 (en) 2005-06-30
NO20042022L (no) 2004-05-14
DE10152351B4 (de) 2005-09-22
PE20030472A1 (es) 2003-06-16

Similar Documents

Publication Publication Date Title
CL2009001279A1 (es) Compuestos derivados de nociceptina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor (sol. divisional 2103-03).
ECSP045238A (es) Forma de dosis oral que contiene un inhibidor de pde 4 como un ingrediente activo y polivinilpirrolidona como excipiente
HN2003000407A (es) Nuevos derivados de fluoroglicosisdos aromaticos, medicamentos que contienen estos compuestos y sus usos.
CR7362A (es) Formulaciones farmaceuticas de derivado de platino
TR199500826A2 (tr) Multipl ünite tablet doz formu 2.
AR059723A2 (es) Composicion de altas dosis de ibandronato
PA8518801A1 (es) Derivados de 2-aminocarbonil-9h-purina
CR7882A (es) Compuestos 2-(1H-Indazol-6-ilamino-benzamidas como inhibidores proteinquinasas utiles para el tratamiento de enfermedades oftalmicas
UY28510A1 (es) Compuestos quimicos
BR9909565A (pt) Derivados bicìclicos do ácido hidroxâmico
PA8582801A1 (es) Nuevos derivados espirotricíclicos y su uso como inhibidores de la fosfodiesterasa
ES2182161T3 (es) Utilizacion de derivados de pirimidina para la preparacion de un medicamento para la prevencion del cancer.
CR8178A (es) Sistemas de emulsion que contienen derivados de azetidina
TR200401603T4 (tr) D vitamini benzerleri
UY31403A1 (es) "derivados novedosos de ({((3-metilfenil)-2h-tetrazol-5-il)-etoxi} -4h-1,2,4-triazol-3-il), composiciones farmacéuticas conteniendolos y uso médico de los mismos".
PA8586801A1 (es) Inhibidores de hiv-integrasa, composiciones farmaceuticas y metodos para su uso
ECSP045493A (es) Nuevas composiciones farmacéuticas que contienen flibanserina polimorfo a
UY27500A1 (es) Formulación sólida para utilizar como medicamento a base de un derivado de piperazinurea
SV1998000119A (es) Formulacion medicamentosa con liberacion controlada de sustancia activa. ref. lea 32671-sv
AR041340A1 (es) Derivados de tiazolpirimidinona,proceso de preparacion y composiciones farmaceuticas que los contienen
UY28715A1 (es) Derivados de diarilmetil piperazina, sus preparaciones y sus usos
AR058047A1 (es) Administracion de inhibidores de dipeptidil peptidasa
AR013559A1 (es) USO DE DERIVADOS DE PIRROLIDINA PARA LA PREPARACIoN DE MEDICAMENNTOS DESTINADOS AL TRATAMIENTO DEL ABUSO DE DROGAS O DE SUSTANCIAS QUE DAN ORIGEN A LA ADICCIoN O AL USO EXCESIVO DE DROGAS , CON EXCEPCIoN DEL ABUSO DEL ALCOHOL, MEDIANTE LA REDUCCIoN DE LA AUTO-MEDICACIoN DE DICHAS DROGAS POR PARTE DE
DE60101370D1 (de) Pharmazeutische zusammensetzungen, die terbinafin enthalten
AR029091A1 (es) Uso de compuestos de 1-amino-5-fenilpentano-3-ol y/o 1-amino-6-fenilhexano-3-ol para la preparacion de un medicamento con efecto antagonista de n-metil-d-aspartato-(nmda)

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150126